Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen

Trial Profile

The phase I,II clinical study of cancer vaccine for intractable malignant tumor expressing MAGE-A4-antigen

Status: Completed
Phase of Trial: Phase I/II

Latest Information Update: 07 Mar 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CHP-MAGE-A4 (Primary) ; Picibanil
  • Indications Cancer
  • Focus Adverse reactions; Pharmacodynamics
  • Most Recent Events

    • 07 Mar 2018 New trial record
    • 01 Mar 2018 Results (n=16) assessing predictive role of CD4+CD25+Foxp3+ regulatory T cells (Tregs) in peripheral blood mononuclear cells (PBMCs) in patients receiving 300 microgram of CHP-MAGE-A4 and 0.5 Klinische Einheit (KE) of OK432 published in the Anticancer Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top